Medifast

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm’s product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medifast reports Q4 revenue decline, focuses on cost management

Medifast's Q4 2022 performance saw revenue decline but strong cost management and cash generation.
Challenges include revenue outlook for Q1 2023 and competitive landscape in weight loss and coaching markets.
Opportunities lie in capital allocation strategies, maintaining shareholder value, and adapting to market trends.
Overall, Medifast remains focused on long-term growth, financial stability, and delivering on its mission.

Medifast surpasses Q1 expectations, eyes growth amid operational tweaks

Medifast's Q1 2023 performance exceeded expectations, with a focus on revenue growth and cost control measures.
Despite challenges like decreased active coaches, the company is well-positioned with a strong financial standing and growth initiatives.
Opportunities in customer acquisition, cost-saving efforts, market expansion, and innovative solutions pave the way for future success.
Guidance for Q2 2023 reflects a strategic approach to balancing growth and profitability amidst market dynamics and operational changes.

Medifast reports Q2 revenue decline, eyes sustainable growth strategies

Medifast navigated challenges in Q2 2023 with improved operating margin and strategic market exits.
The company's focus on new growth initiatives and cost-saving measures reflects adaptability to market dynamics.
While facing revenue declines and competitive pressures, Medifast aims for sustainable growth with clear targets.
Exploration of medically supported weight loss solutions and new product lines offer avenues for future expansion.

Medifast reports resilient Q3 performance, eyes growth through diversification

Medifast's Q3 performance reflects resilience amid revenue decline, with a focus on operational efficiency and financial strength. While facing challenges in revenue and expense management, the company remains agile and proactive in exploring growth opportunities through market expansion and social responsibility initiatives.

Medifast transitions to health and wellness focus amidst revenue challenges

Medifast is navigating challenges in customer acquisition and macro factors while focusing on becoming a diversified health and wellness company.
The company's strategic collaboration with Life MD and new product offerings position it for growth.
While Q4 2023 saw a revenue decrease, Medifast's improved gross profit margin and cost-saving initiatives demonstrate operational efficiency.
Investors should monitor the impact of increased marketing spending on operating margin and EPS in the coming years.

Medifast faces revenue decline due to weight loss medication trends

Medifast's Q1 2024 performance reflects challenges in revenue and income, driven by difficulties in customer acquisition amidst weight loss medication trends.
Despite the decline, the company demonstrated operational efficiency with improved gross profit margins and cost management.
Investments in marketing and collaborations present opportunities for future growth and market expansion, signaling a strategic focus on long-term success.
Navigating market challenges while capitalizing on opportunities will be crucial for Medifast's resilience and competitiveness in the weight loss industry.

Medifast reports Q2 losses, focuses on growth strategies and cost management

Medifast's Q2 2024 performance reflects a challenging period marked by revenue and profit declines, offset by margin improvements and cost reductions.
The company's strategic initiatives aim to drive long-term growth and enhance operational efficiency amidst macroeconomic headwinds and lower coach productivity.
While facing financial setbacks, Medifast's focus on targeted advertising, product diversification, and cost management signifies a proactive stance towards future recovery and growth.

Medifast adapts to industry changes with tailored programs and innovations

Medifast's Q3 2024 performance reflected revenue and net income declines, highlighting challenges in the weight loss industry.
Despite these challenges, the company's strategic focus on tailored programs, strong financial position, and new product launches indicate a proactive approach to addressing market dynamics.
Opportunities in clinical studies, new product launches, and financial strength position Medifast for potential growth and market expansion in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medifast, Inc. is a health and wellness company. engages in the habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple yet comprehensive approach to address obesity and support a healthy lifestyle. The company was founded by William Vitale in 1980 and is headquartered in Baltimore, MD.

LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors With Losses In Medifast Inc Are Urged To Help The Schall Law Firm Investigate Possible Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medifast, Inc. May Have Defrauded The Public And The Schall Law Firm Invites Stockholders To Join A Securities Fraud Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Medifast Inc's Possible Securities Related Infractions And Affected Investors Can Partake

LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medifast, Inc. May Have Committed Securities Fraud And Shareholders With Losses Are Urged To Contribute To The Schall Law Firm's Inquiry

Amid hurdles like competition and a dynamic consumer landscape, Medifast is taking steps to realign its strategy and capitalize on emerging opportunities.

Medifast Trades Near 52-Week Low: Buy, Hold or Sell MED Stock?

LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Medifast Inc's Possible Securities Law Infractions And Investors Are Invited To Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medifast, Inc. May Have Committed Securities Fraud And Shareholders Can Join The Schall Law Firm's Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Medifast Inc For Possible Securities Law Violations And Investors With Losses Should Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medifast, Inc. Might Have Committed Securities Fraud And Impacted Shareholders Can Join The Schall Law Firm's Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Whether Medifast Inc Violated Securities Laws And Investors Can Partake In The Investigation

LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Stakeholders With Losses In Medifast, Inc. Are Urged By The Schall Law Firm To Reach Out About An Inquiry Into Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medifast Inc Might Have Committed Securities Fraud And Investors Should Join The Schall Law Firm's Investigation

LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Whether Medifast Inc. Violated Securities Laws And Impacted Shareholders Can Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors With Losses In Medifast Inc Are Encouraged To Help The Schall Law Firm In A Securities Fraud Investigation

Medifast's collaboration with LifeMD and acquisition of LifeMD shares are expected to boost business growth and free cash flow. The company's holistic approach combining weight loss formulas, coaches, and GLP-1 medication is a significant competitive advantage. Recent investments in marketing and supply chain optimization initiatives, including the Maryland Distribution Center closure, are likely to enhance FCF margins.

Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation

LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Whether Medifast Inc. Violated Securities Regulations And The Public Is Invited To Join

LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medifast Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Seeks Shareholder Participation

LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

An Inquiry By The Schall Law Firm Has Been Launched Into Medifast Inc. For Violating Securities Regulations And Affected Investors Should Reach Out

LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medifast Inc Is Being Looked Into For Securities Fraud And The Schall Law Firm Urges Individuals With Losses To Reach Out

LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Has Launched An Inquiry Into Medifast Inc. For Violating Securities Regulations And Investors Can Take Part

NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medifast, Inc. ("Medifast") (NYSE:MED) concerning possible violations of federal securities laws. Medifast reported its quarterly earnings on April 29, 2024.

Medifast Being Investigated on Behalf of Medifast, Inc. Investors. Contact Levi & Korsinsky For Details

LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medifast Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out

NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medifast, Inc. ("Medifast") (NYSE:MED) concerning possible violations of federal securities laws. Medifast reported its quarterly earnings on April 29, 2024.

Medifast, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - MED

LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited By The Schall Law Firm To Participate In An Inquiry Into Medifast Inc For Securities Law Violations

NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medifast, Inc. ("Medifast") (NYSE:MED) concerning possible violations of federal securities laws. Medifast reported its quarterly earnings on April 29, 2024.

News for Medifast Stock (MED)